Annual report pursuant to Section 13 and 15(d)

Intangible Assets

v3.19.3.a.u2
Intangible Assets
 12 Months Ended
Sep. 30, 2019
Intangible Assets  
Intangible Assets

11. Intangible Assets

The Company’s intangible assets consisted of the following:

 

 

 

 

 

 

 

 

 

 

 

    

September 30, 

    

Estimated useful

 

 

2019

 

2018

 

life (in months)

Clinical trial data

 

$

250,000

 

$

 —

 

 6

Accumulated amortization

 

 

(104,167)

 

 

 —

 

  

Intangible assets, net

 

$

145,833

 

$

 —

 

  

 

Amortization expense for the years ended September 30, 2019 was approximately $104,000. Amortization expense for the period August 28, 2018 (inception) through September 30, 2018 was $0.